Plné znění - 19/2025 Sb.

Sdělení Ministerstva zahraničních věcí, kterým se mění a doplňují sdělení Ministerstva zahraničních věcí č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

19/2025 Sb.
 

Sdělení

INFORMACE

19

SDĚLENÍ

Ministerstva xxxxxxxxxxxx xxxx,

xxxxxx xx xxxx a xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
&xxxx;

Xxxxxxxxxxxx zahraničních xxxx xxxxxxx, že xxx 1. října 2023 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx nového znění Xxxxxxx X - Xxxxxx xxxxxxxxxx látek x xxxxx dopingu xxx xxx 2024 - Mezinárodní xxxxxxxx Xxxxxxxxxxx úmluvy xxxxx xxxxxxx ve sportu.

S xxxxx xxxxxx Xxxxxxx X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx x prezident republiky xxxxxxxx listinu o xxxxxxx xxxx Xxxxxxx X Xxxxxx republikou.

Nové xxxxx Xxxxxxx X xxxxxxxxx v xxxxxxxx x xxxxxxx x článkem 34 xxxx. 3 Xxxxxx dne 1. xxxxx 2024, pro Xxxxxx republiku vstoupilo x xxxxxxxx xxx 18. xxxxxx 2024 x xxxxxxxxx Xxxxxxx X xxx xxx 2023, xxxxxxx xx 1. xxxxx 2023, xxxxx xxxxxxxxx v xxxxxxxx xxx Českou xxxxxxxxx dne 22. xxxxxx 2023 x xxxx vyhlášena xxx č. 32/2023 Sb. m. s.

Xxxxxxxx xxxxx Přílohy X xxx rok 2024 x xxxx xxxxxxx xx xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.
&xxxx;

Xxxxxxx:

x x. JUDr. Xxxxxx, Xx.X., LL.M., x. x.

xxxxxx ředitel xxxxx právní x xxxxxxxxxx
&xxxx;

Xxxxxxx x. 1

Překlad xxxxxxxxxxx smlouvy xx xxxxxxx xxxxxx

Xxxx

Xxxxxx zakázaných xxxxx x metod xxxxxxx xx povinný Xxxxxxxxxxx xxxxxxxx x xxxxx Xxxxxxxxx antidopingového xxxxxxxx.

Xxxxxx xx xxxxxxxxxx xxxxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxxx Xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx (XXXX). Xxxxxx xx xxxxxx xx 1. xxxxx 2024.

Xxxxxxxxx xxxx Xxxxxxx xxxxxxxxxx xxxxx x xxxxx bude xxxxxxxxx XXXX x xxxx publikován x xxxxxxxxxx x xxxxxxxxxxxxx. X xxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx xxxx xxxxxxxxx x francouzským xxxxxx xxxxxxxxx xxxxx v xxxxxxxxxx.

Xxxx xxxx xxxxxxx xxxxxxx xxxxx xxxxxxxxx x xxxxx Xxxxxxx xxxxxxxxxx xxxxx x xxxxx.

Xxxxxxxx Xxx xxxxxxx

Xxxxx XXXX xxx xxxx xxxxx xxxxxxxxxxx jiné xxxxxx, xx xxxxxx Xxx xxxxxxx x xxxxxx obdobím xxxxxxxxxxx xxxxx před půlnocí (xx 23:59 hodin) x den xxxxxxxxxxxxx Xxxxxxx, které xx xx Xxxxxxxxx xxxxxxxxx, xx xx xxxxx Xxxxxxx a xxxxxxx xxxxxx Xxxxxx.

Xxxxxxxx stále

To xxxxxxx, že xxxx xxxxx nebo xxxxxx xx xxxxxxxx Při xxxxxxx i Xxxx xxxxxx, xxx je xxxxxxxxxx x Kodexu.

Specifické x Xxxxxxxxxxxx

Xxxxx xxxxxx 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx Xxxxxx „pro xxxxx xxxxxxxx xxxxxx 10 xxxxx všechny Zakázané xxxxx Specifickými xxxxxxx, x xxxxxxxx těch xxxxxxxxxx v Xxxxxxx xxxxxxxxxx xxxxx x xxxxx dopingu. Xxxxx Xxxxxxxx metoda nebude Xxxxxxxxxxx xxxxxxx, pokud xxxx v Xxxxxxx xxxxxxxxx označena xxxx Xxxxxxxxxx metoda.“ Xxxxx xxxxxxxxx x xxxxxx „Xxxxxxxxxx xxxxx x Xxxxxxxxxx xxxxxx xxxxxxx x xxxxxx 4.2.2 xx neměly xxx xxxxxx způsobem xxxxxxxxxx xx xxxx xxxxxxxx xxxx xxxx xxxxxxxxxx xxx xxxx dopingové xxxxx xxxx metody. Xxx spíše o xxxxx x xxxxxx, xxxxx Xxxxxxxxx xxxxxxxxxxxxx xxxx nebo xxxxxx x xxxxxx xxxxx xxx xx xxxxxxxx xxxxxxxxxxx xxxxxx.“

Xxxxxxxx xxxxx

Xxxxx xxxxxx 4.2.3 Kodexu xxxx Návykové xxxxx xxxxxxxxxx jako látky, xxxxx xxxx xxxx xxxxxx xxxxxxxx z xxxxxx jejich xxxxxxx xxxxxxxxxx xx společnosti xxxx xxxxx xxxxxx. Xxxx Xxxxxxxx xxxxx xxxx xxxxxxxxxx tyto xxxxx: xxxxxx, diamorfin (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (THC).

S0 XXXXXXXXXXX XXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx látky x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxxxx xxxxxxxxxxxxxx xxxxx, xx xxxxxx se xxxxxxxxxx xxxxx z xxxxxxxxxxxxx xxxxxx Xxxxxxx x xxxxx není x xxxxxxxx době schválena xxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxx xxxxxxx použití x xxxx (xxxx. xxxxxx x předklinickém xxxx xxxxxxxxx vývoji nebo xxxxxxx vývoj byl xxxxxxx, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxxx použití), xx zakázána stále.

Tato xxxxx xxxxxxxx xxxxx xxxxxxx xxxxx, mimo xxxx XXX-157, 2,4-xxxxxxxxxxxx (XXX) x aktivátory xxxxxxxxx (xxxx. Reldesemtiv x Xxxxxxxxxx).

X1 XXXXXXXXXX XXXXX

XXXXXXXX STÁLE (PŘI XXXXXXX I MIMO XXXXXX)

Xxxxxxx zakázané xxxxx x této xxxxx xxxx Nespecifické xxxxx.

Xxxxxxxxxx xxxxx xxxx xxxxxxxx.

X1.1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX)

Xxx exogenním xxxxxx, xxxx xxxx xxxxxx:

•	1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3ß, 17ß-diol)		•	formebolon
•	1-androstenedion (5ɑ-androst-1-en-3,17-dion)		•	furazabol (17ɑ-xxxxxx [1,2,5]xxxxxxxxxx[3’,4’:2,3]-5ɑ-xxxxxxxxx-17ß-xx)
•	1-xxxxxxxxxxx (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxx
•	1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxxx
•	1-xxxxxxxxxxx (17ß-hydroxy-5ɑ-androst-1-en-3-on)		•	mesterolon
•	4-androstenediol (xxxxxxx-4-xx-3ß, 17ß-xxxx)		&xxxx;•	xxxxxxxxxxx (17ß-hydroxy-17ɑ-methylandrosta-1,4-dien-3-on)
•	4-hydroxytestosteron(4,17ß-dihydroxyandrost-4-en-3-on)		•	metenolon
•	5-androstenedion (xxxxxxx-5-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx
•	7ɑ-xxxxxxx-XXXX		&xxxx;•	xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx)
•	7ß-xxxxxxx-XXXX		&xxxx;•	xxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxx-5ɑ-xxxxxxx-1-xx-3-xx)
•	7-xxxx-XXXX		&xxxx;•	xxxxxxxxxxxxxx
•	11ß-xxxxx-19-xxxxxxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx (17β-hydroxy-17α-metylestra-4,9-dien-3-on)
•	17ɑ-methylepithiostanol (xxxxxxx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17ß-hydroxy-17ɑ-metylestr-4-en-3-on)
•	19-norandrostenediol (estr-4-en-3,17-diol)		•	metyltestosteron
•	19-norandrostenedion (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx (xxxxxxxxxxxxxx, 17ß-xxxxxxx-17ɑ-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)
•	Xxxxxxx-4-xx-3,11,17-xxxxx(11-xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (5ɑ-xxxxxxxxxxxxxxxxxx, 17ß-xxxxxxx-5ɑ-xxxxxxxxx-3-xx)		&xxxx;•	xxxxxxxxx (19-xxxxxxxxxxxxxx)
•	xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxxxx (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx)
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx
•	xxxxxxxx		&xxxx;•	xxxxxxxx
•	xxxxxxx (androsta-1,4-dien-3,17-dion)		•	oxandrolon
•	calusteron		•	oxymesteron
•	klostebol		•	oxymetolon
•	danazol ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx)		&xxxx;•	xxxxxxxxx (dehydroepiandrosteron, XXXX, 3β-xxxxxxxxxxxxxx-5-xx-17-xx)
•	xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxx-1,4-xxxx-3-xx)		&xxxx;•	xxxxxxxxxxx (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx)
•	xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx x 17ɑ-xxxxx-5ɑ- xxxxxxx-3-xx-17ß- xx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxx		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxxx (3β-xxxxxxx-5α-xxxxxxxxx-17-xx)		&xxxx;•	xxxxxxxxxxx
•	xxx-xxxxxxxxxxxxxxxxxx (17β-hydroxy-5β-androstan-3-on)		•	tetrahydrogestrinon (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxx
•	xxxxxxxxxxxx (19-norpregna-4-en-17α-ol)		•	trenbolon (17β-hydroxyestr-4,9,11-trien-3-on)
•	fluoxymesteron		•	trestolon (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, MENT)

a xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx biologickými xxxxxx.

X1.2. XXXXXXX XXXXXXXXXX XXXXX

Xxxx xxxx xxxxxx:

Xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, selektivní modulátory xxxxxxxxxxxxx receptorů [XXXX, xxxx. andarin, xxxxxxxxx (xxxxxxx), LGD-4033 (xxxxxxxxx), XXX140, X-23 x XX-11], xxxxxxx a xxxxxxxxxx.

X2 PEPTIDOVÉ XXXXXXX, XXXXXXX XXXXXXX, PŘÍBUZNÉ XXXXX A XXXXXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxxxx látky.

Následující látky x xxxxx xxxxx x podobnou xxxxxxxxx xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx jsou xxxxxxxx.

X2.1. XXXXXXXXXXXXX (EPO) X XXXXX XXXXXXXXXXX XXXXXXXXXXX

Xxxx jiné xxxxxx:

X2.1.1 Xxxxxxxx erytropoetinových xxxxxxxxx, xxxx. darbepoetiny (dEPO); xxxxxxxxxxxxx (XXX); xxxxxxxxxx xxxxxxxx na XXX, [xxxx. XXX-Xx, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)]; EPO- xxxxxxxxx xxxxxxxxxx x xxxxxx xxxxxxxxxx, xxxx. XXXX-530, peginesatid.

S2.1.2 Xxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (HIF), např. xxxxxx; xxxxxxxxxxx (GSK1278863); XXX2; xxxxxxxxxx (XXX 85-3934); roxadustat (XX-4592); xxxxxxxxxx (AKB-6548); xxxxx.

X2.1.3 Xxxxxxxxxx XXXX, xxxx. X-11706.

X2.1.4 Xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxx faktoru xxxx (XXX-β), např. xxxxxxxxxxxx; xxxxxxxxxxx.

X2.1.5 Xxxxxxxx xxxxxxxxx xxxxxxxxx xxxxxxxxx, xxxx. xxxxxx XXX; xxxxxxxxxxxxx EPO (XXXX).

X2.2. XXXXXXXXX XXXXXXX X XXXXXX XXXXXXXXXX XXXXXXX

X2.2.1 Xxxxxxx xxxxxxxxxxx xxxxxxxxxxx x mužů, mimo xxxx xxxxxx:

• xxxxxxxx xxxxxxxxxxxx (XX),

• xxxxxxxxxxxx xxxxxx (LH),

• xxxxxx xxxxxxxxxx gonadotropin (XxXX, xxxxxxxxxxx) x xxxx xxxxxxxxxxx xxxxxxx (např. xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, leuprorelin, xxxxxxxxx x xxxxxxxxxxx),

&xxxx;• xxxxxxxxxx x xxxx xxxxxxxxxxx xxxxxxx.

X2.2.2 Kortikotropiny a xxxxxx xxxxxxxxxx faktory, xxxx. xxxxxxxxxxxx a xxxxxxxxxxxxx.

X2.2.3 Xxxxxxx xxxxxx (XX), jeho analogy x fragmenty, xxxx xxxx xxxxxx:

• xxxxxxx xxxxxxxxx hormonu, např. xxxxxxxxxxxxxxxxx, somapacitan x xxxxxxxxxx,

• xxxxxxxxx růstového xxxxxxx, např. AOD-9604 x hGH 176–191.

S2.2.4 Xxxxxxx xxxxxxxxxx xxxxxxx xxxxxx, xxxx xxxx xxxxxx:

• hormon xxxxxxxxxx xxxxxxx xxxxxx (GHRH) x jeho xxxxxxx, xxxx. XXX-1293, XXX-1295, xxxxxxxxxx x tesamorelin,

• xxxxxxxxxxx xxxxxxxxx hormonu (XXX) x jejich xxxxxxxx [xxxx. anamorelin, xxxxxxxxxxxx, xxxxxxxxxx (MK-677), xxxxxxxxxx, xxxxxxxxxxx (xxxxxxx), xxxxxxxxxxx x xxxxxxxxxxx],

• xxxxxxx xxxxxxxxxx GH (XXXX) [např. xxxxxxxxxxxx, xxxxxxxxxx (hexarelin), GHRP-1, XXXX-2 (xxxxxxxxxxx), XXXX-3, XXXX-4, GHRP-5 a XXXX-6].

X2.3. RŮSTOVÉ XXXXXXX X XXXXXXXXXX XXXXXXXXX XXXXXXX

Xxxx xxxx včetně:

• xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXX)

• xxxxxxxxxxxx xxxxxxx xxxxxx (XXX)

• růstový xxxxxx 1 podobný xxxxxxxx (XXX-1, xxxxxxxxxx) x jeho xxxxxxx

• xxxxxxxxxx růstové xxxxxxx (XXX)

• xxxxxxx faktor xxxxxxxx x xxxxxxxx xxxxxxxx (PDGF)

• thymosin-β4 x xxxx xxxxxxxx, xxxx. XX-500

• vaskulárně-endoteliární xxxxxxx xxxxxx (XXXX)

x xxxxx xxxxxxx xxxxxxx xxxx xxxxxxxxxx růstových xxxxxxx xxxxxxxxxxx xxxxxxx/xxxxxxxxx xxxxxxxx xx xxxxxxx, xxxxxxxx xxxx vazech, xxxxxxxxxxxxx, xxxxxxx energie, xxxxxxxxxxxxx xxxxxxxx nebo xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.

X3 XXXX-2 XXXXXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX SOUTĚŽ)

Všechny xxxxxxxx látky x xxxx xxxxx xxxx Xxxxxxxxxx látky.

Všichni selektivní x xxxxxxxxxxxx beta-2 xxxxxxxx xxxxxx xxxxx xxxxxxxxx xxxxxxx xxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

XXXXXXX

• Xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 xxxxxxxxxx xx 24 xxxxx x oddělených xxxxxxx, xxxxxxxxxxxxxxxx 600 xxxxxxxxxx xxxxx 8 xxxxx xx xxxxxxxxx dávce;

• xxxxxxxxx formoterol: maximálně xxxxxx xxxxx 54 xxxxxxxxxx za 24 xxxxx;

• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 xxxxx;

• xxxxxxxxx vilanterol: xxxxxxxxx 25 xxxxxxxxxx za 24 hodin.

POZNÁMKA

Přítomnost xxxxxxxxxxx x xxxx v xxxxxxxx xxxxxx než 1000 xx/xx xxxx xxxxxxxxxxx v xxxxxxxx xxxxxx než 40 xx/xx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx látky x xxxx xxxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), pokud Xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, že abnormální xxxxxxxx xxx xxxxxxxxx xxxxxxxxxxxx dávky (xxxxxxxxx) xx xx výše xxxxxxx xxxxxxxxx xxxxx.

X4 XXXXXXXXX X METABOLICKÉ XXXXXXXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX X XXXX XXXXXX)

Xxxxxxxx látky xx xxxxxxx X4.1 x X4.2 xxxx Xxxxxxxxxx xxxxx.

Xxxxx xxxxxxxx do xxxx X4.3 x X4.4 xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx xxxxxxxxx a xxxxxxxxxxx xxxxxxxxxx jsou xxxxxxxx.

X4.1. INHIBITORY XXXXXXXX

Xxxx xxxx včetně:

•	2-androstenol (5ɑ-androst-2-en-17-ol)		•	androsta-1,4,6-trien-3,17-dion (xxxxxxxxxxxxxxxxx)
•	2-xxxxxxxxxxx (5ɑ-androst-2-en-17-on)		•	androsta-3,5-dien-7,17-dion (xxxxxxxxx)
•	3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	4-xxxxxxxxx-3,6,17 xxxxx (6-xxx)		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx

X4.2. XXXXXXXXXXXXXX XXXXX [XXXXXXXXXXXXX X SELEKTIVNÍ XXXXXXXXXX XXXXXXXXXXXXX RECEPTORŮ (XXXXX)]

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

X4.3. XXXXX XXXXXXXXXXX XXXXXXXX RECEPTORU XXXXXXXX XXX

Xxxx xxxx xxxxxx:

•	xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx X		•	xxxxxxxxxx xxxxxxxxxx, xxxx.:
•	xxxxxxxxxx xxxxxxxxx xxxxxxxx XXX, xxxx.:			- xxxxx xxxxxxxxx xxxx xxxxxx expresi myostatinu
	- xxxxxxx xxxxxxxxx xxxxxxxx (xxxx. XXX-031)			- proteiny xxxxxx xxxxxxxxx (např. xxxxxxxxxxx, xxxxxxxxx myostatinu)
•	protilátky xxxxx receptoru xxxxxxxx XXX (např. bimagrumab)			- xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxxxx (xxxx. xxxxxxxxxxx, xxxxxxx xxxxx, xxxxxxxxxxxxx, stamulumab)

S4.4. XXXXXXXXXXX XXXXXXXXXX

X4.4.1 xxxxxxxxxx AMP-aktivované xxxxxxxxxxxxx (XXXX), xxxx. XXXXX, xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx (PPARδ), xxxx. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (trifluormetyl)fenyl)thiazol-5-yl)metylthio)fenoxy) kyselina xxxxxx (XX1516, XX501516) x xxxxxxxx Xxx-xxxɑ , např. XX9009, XX9011

X4.4.2 xxxxxxxx x xxxxxxxx xxxxxxxx

X4.4.3 meldonium

S4.4.4 xxxxxxxxxxxx

X5 XXXXXXXXX X XXXXXXXXX LÁTKY

ZAKÁZANÉ STÁLE (XXX XXXXXXX I XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx v xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx xxxxxxxxx a xxxxxxxxx xxxxx, xxxxxx xxxxx optických xxxxxxx, xxxx. x- x x-, xxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

•&xxxx; Diuretika, xxxx např.:

acetazolamid; xxxxxxxx; xxxxxxxxx; xxxxxxxx; xxxxxxxxxxxx; xxxxxxxx xxxxxxxxxx; xxxxxxxxx; xxxxxxxxx; metolazon; xxxxxxxxxxxxx; xxxxxxxx, xxxx. bendroflumethiazid, xxxxxxxxxxxxx x xxxxxxxxxxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx;

• Xxxxxxx, xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx;

• Xxxxxxxxxxx xxxxxxxxx xxxxxxxx xxxxxxxxxxxx, např.:

albumin, xxxxxxx, xxxxxxxxxxx xxxxx, xxxxxxxx;

• Xxxxxxxxxxx;

• Xxxxxxxxxx;

x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

XXXXXXX

• xxxxxxxxxxx; xxxxxxxx; x xxxxxxx xxxxxxxxxxxxxx xxxxxxxx inhibitorů karboanhydrázy (xxxx. dorzolamid, brinzolamid);

• xxxxxxx xxxxxx felypresinu x xxxxx xxxxxxxxx.

XXXXXXXX

Xxxxx xxxxxxxxxxx xxxxxxxx látky xx stanoveným prahovým xxxxxxx: x formoterolu, xxxxxxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxxxxxx x xxxxxxxxxxxxxx xx Vzorku Xxxxxxxxx xxxxxxxx xxxx xxxxxxxx Xxx Xxxxxxx ve xxxxxxx x xxxxxxxxxx xxxx xxxxx xxxxxxxxx xxxxxx (xxxxx xxxxxxxxx xxxxxx xxxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx felypresinu v xxxxxxxx anestezii), xxxx xxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx nález (AAF), xxxxx Xxxxxxxxx xxxx xxxxxxxxxx Xxxxxxxxxxxxx xxxxxxx (XX) xx tuto xxxxx navíc x xx, xxxxx xxx xxxx xxxxxxx na xxxxxxxxxx nebo jinou xxxxxxxxx látku.

ZAKÁZANÉ METODY

ZAKÁZANÉ XXXXX (PŘI SOUTĚŽI X XXXX SOUTĚŽ)

Všechny xxxxxxxx xxxxxx x xxxx třídě xxxx Xxxxxxxxxxxx x xxxxxxxx xxxxx x M2.2, xxx xxxx Xxxxxxxxxx xxxxxx.

X1. MANIPULACE X XXXX X XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx je xxxxxxxxxxx:

X1.1. Xxxxxx nebo opětovné xxxxxxxx xxxxxxxxxxx xxxxxxxx xxxxxxxxx, xxxxxxxxx (xxxxxxxxx) xxxx xxxxxxxxxxx xxxx xxxx xxxxxxxx x xxxxxxxxx xxxxxxx jakéhokoliv xxxxxx xx xxxxxxxxx xxxxxxx x výjimkou xxxxxxxx xxxxxx xxxx xxxxxx xxxxxx Xxxxxxxxx xxxxxxxxxxxxxxx plazmaferézy xxxxxxxxx x xxxxxxxxxxxxx xxxxxxxxx xxxxxx.

X1.2. Xxxxx xxxxxxxxx xxxxxx, přenosu xxxx xxxxxxx xxxxxxx.

Xxxx xxxx xxxxxx:

Xxxxxxxxxxxxxxxxxxx; efaproxiral (RSR13); xxxxxxxxx x modifikované xxxxxxxxxxxxx produkty, např. xxxxxx xxxxxxxx na xxxx hemoglobinu x xxxxxxxxxxxxxxxx hemoglobinové produkty, x xxxxxxxx doplňkového xxxxxxx xxxxxxxx.

X1.3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx manipulace x xxxx xxxx x xxxxxxxx xxxxxxxxxxxx xxxxxxxxxxx xxxx chemickými xxxxxxx.

X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X2.1. Podvádění nebo Xxxxx x podvod xx xxxxxx porušit xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx při Xxxxxxxxx kontrole.

Mimo jiné xxxxxx:

Xxxxxx x/xxxx xxxxxx Xxxxxx, xxxx. přidáním xxxxxxx ke Xxxxxx.

X2.2. Xxxxxxxxxx infuze x/xxxx xxxxxxx více než xxxxxx 100 xx xx 12 xxxxx xxxxx infuzí xxxxxxxxx xxxxxxxxx x průběhu xxxxxxxxxxxx xxxxxxxx, xxxxxxxxxxxxx xxxxxxx xxxx klinických xxxxxxxxxxxxxx vyšetření.

M3. XXXXXX X XXXXXXX XXXXXX

X xxxxxx xxxxxxxxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxx je xxxxxxxx xxxxxxxxxxx:

X3.1. Xxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx analogů, xxxxx xxxxx xxxxxx xxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxx. Xx xxxx xxxx xxxxxxxx xxxxxxxxxxx xxxxx xxxx, xxxxxxxxx xxxx x xxxxxxxxxxx přenosů xxxx.

X3.2. Xxxxxxx normálních xxxx geneticky xxxxxxxxxxxxxx xxxxx.

X6 XXXXXXXXXXX

XXXXXXXX XXX XXXXXXX

Xxxxxxx xxxxxxxx látky x této xxxxx xxxx Xxxxxxxxxx látky x xxxxxxxx xxxxx xxxxxxxxx x X6.X, xxx xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxx xxxxx x xxxx xxxxx: xxxxxx x xxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“)

Xxxxxxx xxxxxxxxxxx, xxxxxx všech xxxxxxxxx izomerů, např. x- x l-, xxxx xxxxxxxx.

Xxxxxxxxxxx zahrnují:

S6.A: XXXXXXXXXXXX XXXXXXXXXXX

•	xxxxxxxxx		•	xxxxxxxxxxxx [4-fenylpiracetam (xxxxxxxx)]
•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxx(x-)
•	xxxxxxxxx		•	x-xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx
•	xxxxxxxxxxx

Xxxxxxxxx, který xxxx xxxxxxxx xxxxxx v xxxxx oddíle, xx Xxxxxxxxxxx xxxxxx.

X6.X: XXXXXXXXXX XXXXXXXXXXX

Xxxx jiné včetně:

•	2-fenylpropan-1-amin (ß-xxxxxxxxxxxxxx-xxxx, XXXXX)		•	xxxxxxxxxxx		•	xxxxxxxxx
•	3-xxxxxxxxxx-2-xxxx (1,2-dimetylpentylamin)		•	fenbutrazát		•	oxilofrin (xxxxxxxxxxxxx)
•	4-xxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxx
•	4-xxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxx, 1,3 XXXX, xxxxxxxxxxxxxx)		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	4-xxxxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxxxx)		•	xxxxxxxxxx (xxxxxxxxx)		•	xxxxxxxxxxx a xxxx xxxxxxxx
•	5-xxxxxxxxxx-2-xxxx (1,4-dimetylamylamin, 1,4-xxxxxxxxxxxxxxxxx, 1,4-XXXX)		•	xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx)		•	xxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxx1)		•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxx x xxxx xxxxxxx, xxxx. xxxxxxxx, xxxxxxxx x ɑ-xxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx2)
•	xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxx)		•	xxxxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxx3)		•	xxxxxxxxxxxx3)		•	xxxxxxxxxx
•	xxxxxxxxx (xxxxxxxxx)4)		•	xxxxxxxxxxxxx [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- xx)xxxxxx]		•	xxxxxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx)
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxx (1,5-xxxxxxxxxxxxxxxx)

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx

XXXXXXX

• klonidin;

• xxxxxxxx imidazolinu v xxxxxxx xxxxxx xxxxxxx, xxxxxxx, očního xxxx xxxxxx xxxxxxx (xxxx. xxxxxxxxxx, klonazolin, fenoxazolin, xxxxxxxxxxx, nafazolin, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xylometazolin) x stimulancia xxxxxxxx xx Monitorovacího programu 2024⁵⁾.

X7 NARKOTIKA

ZAKÁZANÉ XXX XXXXXXX

Xxxxxxx xxxxxxxx látky x xxxx xxxxx xxxx Xxxxxxxxxx látky.

Návykové xxxxx v xxxx xxxxx: xxxxxxxxx (xxxxxx)

Xxxxxxxxxxx xxxxxxxxx, včetně jejich xxxxxxxxxx všech xxxxxxxxx xxxxxxx, xxxx. d- x l, jsou xxxxxxxx.

•	xxxxxxxxxxx		•	xxxxxxxx x jeho xxxxxxxx		•	xxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx
•	xxxxxxxxx (heroin)		•	metadon		•	oxykodon		•	tramadol
						•	oxymorfon

S8 XXXXXXXXXXX

XXXXXXXX XXX SOUTĚŽI

Všechny zakázané xxxxx v xxxx xxxxx xxxx Xxxxxxxxxx xxxxx. Xxxxxxxx xxxxx x této xxxxx: xxxxxxxxxxxxxxxxxxx (XXX)

Xxxxxxx xxxxxxxx x xxxxxxxxxx xxxxxxxxxxx xxxx zakázané, xxxx.

• x konopí (hašiš, xxxxxxxxx) x xxxxxxxxx xxxxxxxxxx

• xxxxxxxx x xxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx (XXX)

• xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx xxxxxx THC

VÝJIMKY

• xxxxxxxxxx

X9 XXXXXXXXXXXXXXX

XXXXXXXX PŘI XXXXXXX

Xxxxxxx xxxxxxxx látky v xxxx třídě xxxx Xxxxxxxxxx látky.

Všechny xxxxxxxxxxxxxxx xxxx zakázány, xxxxx xxxx xxxxxxxx xxxxxxxxxx xxxxxxxx, xxxxxxxxx [xxxxxx xxxxxxxxxx (xxxx. bukální, xxxxxxxxxx, sublingvální)] xxxx xxxxxxxx cestou.

Mimo jiné xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxxx acetonid
•	kortizon		•	hydrokortizon
•	deflazakort		•	metylprednisolon

POZNÁMKA

• Jiné xxxxxxx podání (xxxxxx xxxxxxxxxxx x xxxxxxxxx: xxxxxxxx-xxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, xxxxxx a xxxxxxxxxxxx) nejsou xxxxxxxx, xxxxx xx xxxxxxxxx x xxxxx xxxxxxxx xxxxxxxxxxxx xxxxx x xxxxxxxxxxxxxx xxxxxxxx.

X1 XXXX-XXXXXXXXX

XXXXXXXX X XXXXXXXX SPORTECH

Všechny xxxxxxxx látky v xxxx třídě xxxx Xxxxxxxxxx xxxxx.

Xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx x xxxxxxxxxxxxx sportech Xxx Xxxxxxx x kde xx xx xxxxxxxx xxxxxxxx (*) x Xxxx xxxxxx.

• xxxxxxxxxxx (XX)*

• lyžování/snowboarding (FIS) – xxxxx na xxxxxx, xxxxxxxxxxx skoky / U-rampa x xxxxxxxxx X-xxxxx / xxx air

• xxxxxxxxxxxx xxxxx (XXX)

• xxxxxxxx xxxxxx (XXXX)* x xxxxxxxxxxxx xxxxxxx xxxxxxxx, xxxx xxxxxxxx x xxxxxxx xx xxxx

• xxxxxxxx (xxxxxxx disciplíny) (XXXX)

• šipky (XXX)

• xxxx (IGF)

• xxxxxxxx (XXX)

• xxxxxxx (XXXX, XXX)*

* xxxxxxxx xxxx Xxxx soutěž

Mimo xxxx xxxxxx:

•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxx
•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxx

Xxxxxxx x. 2

Znění xxxxxxxxxxx xxxxxxx x xxxxxxxxx xxxxxx
&xxxx;

¹⁾ katin (x-xxxxxxxxxxxxxxxx) a jeho x-xxxxxx: xx xxxxxxxx xxxxx xxx koncentraci x moči vyšší xxx 5 xxxxxxxxxx x 1 xx.

²⁾ xxxxxxxxxxxxx: zakázaný xxxxx xxx koncentraci x xxxx vyšší než 150 xxxxxxxxxx x 1 xx.

³⁾ xxxxxxx x xxxxxxxxxxxx: xxxxxxxx xxx xxxxxxxxxxx x xxxx xxxxx xxx 10 xxxxxxxxxx x 1 xx.

⁴⁾ epinefrin (xxxxxxxxx): není zakázáno xxxxxxx xxxxxxxx, xxxx. xxxxx, xxxx, xxxx xxxxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxx.

⁵⁾ bupropion, xxxxxxxxxx, fenylpropanolamin, xxxxxx, xxxxxxx, xxxxxxxxx a xxxxxxxx: xxxx látky xxxx xxxxxxxx xx Xxxxxxxxxxxxxx programu 2024 x xxxxxx xxxxxxxxxx xx Xxxxxxxx xxxxx.

Xxxxxxxxx

Xxxxxx xxxxxxx x. 19/2025 Xx. nabyl xxxxxxxxx xxxx 28.1.2024.

Znění xxxxxxxxxxxx xxxxxxxx norem xxxxxx xxxxxxxx xxxxxxxx x odkazech není xxxxxxxxxxxxx, xxxxx se xxxx xxxxxx derogační xxxxx shora xxxxxxxxx xxxxxxxx xxxxxxxx